Q-omics provides the consensus-scored APOL6 profile across patient tissues and cancer cell-line models. APOL6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, APOL6 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, APOL6 RNA expression shows 19,641 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight SKCM, KIRC, and KIRP as cancer lineages where APOL6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for APOL6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes APOL6 survival associations across molecular data types. APOL6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible APOL6 RNA expression–survival associations across cancer types. High APOL6 expression shows unfavorable associations in UVM, LGG and PAAD, but favorable associations in SKCM, BLCA and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for APOL6 RNA expression.
This table summarizes APOL6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for APOL6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. APOL6 shows lower tumor expression in BRCA and LUSC and higher tumor expression in KIRC, STAD, HNSC and ESCA. The KIRC box plot shows higher APOL6 RNA expression in tumor versus normal tissue (log2 FC = +1.443, t-test p < 0.001).
This table shows molecular features associated with APOL6 in patient tissues and cancer cell lines. In patient samples, APOL6 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, APOL6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
